AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATRA
  4. [Form 4] Atara Biotherapeutics, Inc Insider Trading Activity

[Form 4] Atara Biotherapeutics, Inc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Panacea Innovation Ltd, a reporting person linked to Atara Biotherapeutics, Inc. (ATRA), acquired 55,000 shares of Atara common stock on 08/15/2025 at a weighted-average price of $12.1895 per share. After the transaction, the reporting persons disclose beneficial ownership of 1,405,000 shares held indirectly. The filing identifies Panacea Innovation Limited and James Huang (who is the sole owner of Panacea Innovation Limited) as reporting persons and explains that Panacea entities hold securities through Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P.; the filing also includes a disclaimer that the reporting persons may be deemed to share beneficial ownership but disclaim such ownership. The price reported is a weighted average of multiple purchases ranging from $11.83 to $12.44.

Panacea Innovation Ltd, soggetto obbligato correlato a Atara Biotherapeutics, Inc. (ATRA), ha acquisito 55.000 azioni ordinarie di Atara il 15/08/2025 a un prezzo medio ponderato di $12,1895 per azione. Dopo l鈥檕perazione, i soggetti segnalanti dichiarano la detenzione beneficiaria indiretta di 1.405.000 azioni. La comunicazione individua Panacea Innovation Limited e James Huang (unico proprietario di Panacea Innovation Limited) come soggetti segnalanti e specifica che le entit脿 Panacea detengono titoli tramite Panacea Venture Healthcare Fund II, L.P. e Panacea Opportunity Fund I, L.P.; include inoltre una dichiarazione di non piena condivisione della titolarit脿 beneficiaria, pur riconoscendone la possibilit脿. Il prezzo indicato 猫 una media ponderata di acquisti multipli compresi tra $11,83 e $12,44.

Panacea Innovation Ltd, persona informante vinculada a Atara Biotherapeutics, Inc. (ATRA), adquiri贸 55.000 acciones ordinarias de Atara el 15/08/2025 a un precio ponderado medio de $12,1895 por acci贸n. Tras la operaci贸n, las personas informantes declaran la propiedad beneficiaria indirecta de 1.405.000 acciones. La presentaci贸n identifica a Panacea Innovation Limited y a James Huang (煤nico propietario de Panacea Innovation Limited) como personas informantes y explica que las entidades Panacea mantienen valores a trav茅s de Panacea Venture Healthcare Fund II, L.P. y Panacea Opportunity Fund I, L.P.; incluye asimismo una salvedad por la posible compartici贸n de la titularidad beneficiaria, que niegan. El precio informado es un promedio ponderado de m煤ltiples compras que van desde $11,83 hasta $12,44.

Panacea Innovation Ltd電� Atara Biotherapeutics, Inc. (ATRA)鞕� 鞐瓣磤霅� 氤搓碃鞚胳溂搿滌劀 55,000欤�鞚� Atara 氤错喌欤茧ゼ 2025-08-15鞐� 欤茧嫻 韽夑窢 臧�欷戧皜瓴� $12.1895鞐� 旆摑頄堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃鞚鸽摛鞚� 臧勳爲鞝侅溂搿� 1,405,000欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃╇媹雼�. 鞝滌稖氍胳劀鞐愲姅 Panacea Innovation Limited鞕� 頃措嫻 須岇偓鞚� 雼弲 靻岇湢欤检澑 James Huang臧� 氤搓碃鞚胳溂搿� 氇呾嫓霅橃柎 鞛堨溂氅�, Panacea 瓿勳棿鞚� Panacea Venture Healthcare Fund II, L.P. 氚� Panacea Opportunity Fund I, L.P.毳� 韱淀暣 歃濌秾鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 靹る獏頃╇媹雼�. 霕愴暅 氤搓碃鞚鸽摛鞚� 鞁れ鞝� 靻岇湢甓岇潉 瓿奠湢頃橂姅 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨毵� 鞚措ゼ 攵�鞚疙暅雼る姅 氅挫眳臁绊暛鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 臧�瓴╈潃 $11.83鞐愳劀 $12.44 靷澊鞚� 鞐煬 毵れ垬鞚� 臧�欷戫弶攴犾瀰雼堧嫟.

Panacea Innovation Ltd, personne d茅clarante li茅e 脿 Atara Biotherapeutics, Inc. (ATRA), a acquis 55 000 actions ordinaires d鈥橝tara le 15/08/2025 脿 un prix moyen pond茅r茅 de 12,1895 $ par action. Apr猫s la transaction, les personnes d茅clarante divulguent la propri茅t茅 b茅n茅ficiaire indirecte de 1 405 000 actions. le d茅p么t identifie Panacea Innovation Limited et James Huang (propri茅taire unique de Panacea Innovation Limited) comme personnes d茅clarante et pr茅cise que les entit茅s Panacea d茅tiennent des titres via Panacea Venture Healthcare Fund II, L.P. et Panacea Opportunity Fund I, L.P. ; il comprend 茅galement une clause indiquant que les personnes d茅clarante pourraient 锚tre consid茅r茅es comme partageant la propri茅t茅 b茅n茅ficiaire, qu鈥檈lles contestent toutefois. Le prix d茅clar茅 est une moyenne pond茅r茅e d鈥檃chats multiples comprises entre 11,83 $ et 12,44 $.

Panacea Innovation Ltd, eine meldepflichtige Person im Zusammenhang mit Atara Biotherapeutics, Inc. (ATRA), erwarb am 15.08.2025 55.000 Aktien der Atara-Stammaktien zu einem gewichteten Durchschnittspreis von $12,1895 pro Aktie. Nach der Transaktion geben die meldenden Personen den wirtschaftlichen indirekten Besitz von 1.405.000 Aktien an. Die Einreichung benennt Panacea Innovation Limited und James Huang (einziger Eigent眉mer von Panacea Innovation Limited) als meldende Personen und erkl盲rt, dass Panacea-Gesellschaften Wertpapiere 眉ber Panacea Venture Healthcare Fund II, L.P. und Panacea Opportunity Fund I, L.P. halten; au脽erdem enth盲lt die Einreichung einen Haftungsausschluss, wonach den meldenden Personen eine geteilte wirtschaftliche Eigent眉merschaft zugeschrieben werden k枚nnte, die sie jedoch bestreiten. Der angegebene Preis ist ein gewichteter Durchschnitt mehrerer K盲ufe im Bereich von $11,83 bis $12,44.

Positive
  • Insider-affiliated purchase: 55,000 shares acquired on 08/15/2025 shows a controlled-party acquisition
  • Transparent pricing: Weighted-average price disclosed at $12.1895 with a purchase range of $11.83鈥�$12.44
  • Clear ownership disclosure: Post-transaction indirect beneficial ownership reported as 1,405,000 shares and ownership chain explained
Negative
  • None.

Insights

TL;DR: Insider-affiliated entity bought 55,000 ATRA shares at ~$12.19, modestly increasing indirect stake to 1.405M shares.

The purchase reported on Form 4 is a clear, documented open-market acquisition by an entity controlled by James Huang. The weighted-average price and disclosed price range provide transparent execution detail. The post-transaction indirect beneficial ownership of 1,405,000 shares is significant for disclosure purposes but the filing does not state percentage ownership relative to outstanding shares, limiting assessment of scale. No options or derivative transactions were reported. Impact is generally positive as insider-affiliated purchases can signal alignment, but materiality depends on company share count and investor context.

TL;DR: Filing shows compliant disclosure of insider-related purchases and ownership chain with appropriate signatures.

The Form 4 properly lists both the reporting entity (Panacea Innovation Ltd) and an individual (James Huang) with director and 10% owner checkboxes. The filing includes explanatory footnotes clarifying ownership structure and a standard disclaimer regarding shared beneficial ownership. The disclosure is procedurally complete: transaction date, weighted-average price range, and post-transaction holdings are reported, and the form is signed. The filing does not include any amendments or related-party transaction statements beyond ownership linkage.

Panacea Innovation Ltd, soggetto obbligato correlato a Atara Biotherapeutics, Inc. (ATRA), ha acquisito 55.000 azioni ordinarie di Atara il 15/08/2025 a un prezzo medio ponderato di $12,1895 per azione. Dopo l鈥檕perazione, i soggetti segnalanti dichiarano la detenzione beneficiaria indiretta di 1.405.000 azioni. La comunicazione individua Panacea Innovation Limited e James Huang (unico proprietario di Panacea Innovation Limited) come soggetti segnalanti e specifica che le entit脿 Panacea detengono titoli tramite Panacea Venture Healthcare Fund II, L.P. e Panacea Opportunity Fund I, L.P.; include inoltre una dichiarazione di non piena condivisione della titolarit脿 beneficiaria, pur riconoscendone la possibilit脿. Il prezzo indicato 猫 una media ponderata di acquisti multipli compresi tra $11,83 e $12,44.

Panacea Innovation Ltd, persona informante vinculada a Atara Biotherapeutics, Inc. (ATRA), adquiri贸 55.000 acciones ordinarias de Atara el 15/08/2025 a un precio ponderado medio de $12,1895 por acci贸n. Tras la operaci贸n, las personas informantes declaran la propiedad beneficiaria indirecta de 1.405.000 acciones. La presentaci贸n identifica a Panacea Innovation Limited y a James Huang (煤nico propietario de Panacea Innovation Limited) como personas informantes y explica que las entidades Panacea mantienen valores a trav茅s de Panacea Venture Healthcare Fund II, L.P. y Panacea Opportunity Fund I, L.P.; incluye asimismo una salvedad por la posible compartici贸n de la titularidad beneficiaria, que niegan. El precio informado es un promedio ponderado de m煤ltiples compras que van desde $11,83 hasta $12,44.

Panacea Innovation Ltd電� Atara Biotherapeutics, Inc. (ATRA)鞕� 鞐瓣磤霅� 氤搓碃鞚胳溂搿滌劀 55,000欤�鞚� Atara 氤错喌欤茧ゼ 2025-08-15鞐� 欤茧嫻 韽夑窢 臧�欷戧皜瓴� $12.1895鞐� 旆摑頄堨姷雼堧嫟. 瓯半灅 頉� 氤搓碃鞚鸽摛鞚� 臧勳爲鞝侅溂搿� 1,405,000欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 瓿店皽頃╇媹雼�. 鞝滌稖氍胳劀鞐愲姅 Panacea Innovation Limited鞕� 頃措嫻 須岇偓鞚� 雼弲 靻岇湢欤检澑 James Huang臧� 氤搓碃鞚胳溂搿� 氇呾嫓霅橃柎 鞛堨溂氅�, Panacea 瓿勳棿鞚� Panacea Venture Healthcare Fund II, L.P. 氚� Panacea Opportunity Fund I, L.P.毳� 韱淀暣 歃濌秾鞚� 氤挫湢頃橁碃 鞛堨潓鞚� 靹る獏頃╇媹雼�. 霕愴暅 氤搓碃鞚鸽摛鞚� 鞁れ鞝� 靻岇湢甓岇潉 瓿奠湢頃橂姅 瓴冹溂搿� 臧勳＜霅� 靾� 鞛堨毵� 鞚措ゼ 攵�鞚疙暅雼る姅 氅挫眳臁绊暛鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氤搓碃霅� 臧�瓴╈潃 $11.83鞐愳劀 $12.44 靷澊鞚� 鞐煬 毵れ垬鞚� 臧�欷戫弶攴犾瀰雼堧嫟.

Panacea Innovation Ltd, personne d茅clarante li茅e 脿 Atara Biotherapeutics, Inc. (ATRA), a acquis 55 000 actions ordinaires d鈥橝tara le 15/08/2025 脿 un prix moyen pond茅r茅 de 12,1895 $ par action. Apr猫s la transaction, les personnes d茅clarante divulguent la propri茅t茅 b茅n茅ficiaire indirecte de 1 405 000 actions. le d茅p么t identifie Panacea Innovation Limited et James Huang (propri茅taire unique de Panacea Innovation Limited) comme personnes d茅clarante et pr茅cise que les entit茅s Panacea d茅tiennent des titres via Panacea Venture Healthcare Fund II, L.P. et Panacea Opportunity Fund I, L.P. ; il comprend 茅galement une clause indiquant que les personnes d茅clarante pourraient 锚tre consid茅r茅es comme partageant la propri茅t茅 b茅n茅ficiaire, qu鈥檈lles contestent toutefois. Le prix d茅clar茅 est une moyenne pond茅r茅e d鈥檃chats multiples comprises entre 11,83 $ et 12,44 $.

Panacea Innovation Ltd, eine meldepflichtige Person im Zusammenhang mit Atara Biotherapeutics, Inc. (ATRA), erwarb am 15.08.2025 55.000 Aktien der Atara-Stammaktien zu einem gewichteten Durchschnittspreis von $12,1895 pro Aktie. Nach der Transaktion geben die meldenden Personen den wirtschaftlichen indirekten Besitz von 1.405.000 Aktien an. Die Einreichung benennt Panacea Innovation Limited und James Huang (einziger Eigent眉mer von Panacea Innovation Limited) als meldende Personen und erkl盲rt, dass Panacea-Gesellschaften Wertpapiere 眉ber Panacea Venture Healthcare Fund II, L.P. und Panacea Opportunity Fund I, L.P. halten; au脽erdem enth盲lt die Einreichung einen Haftungsausschluss, wonach den meldenden Personen eine geteilte wirtschaftliche Eigent眉merschaft zugeschrieben werden k枚nnte, die sie jedoch bestreiten. Der angegebene Preis ist ein gewichteter Durchschnitt mehrerer K盲ufe im Bereich von $11,83 bis $12,44.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Panacea Innovation Ltd
(Last) (First) (Middle)
C/O MAPLES CORPORATE SERVICES LIMITED,
UGLAND HOUSE
(Street)
GRAND CAYMAN E9 KY1-1104
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Atara Biotherapeutics, Inc. [ ATRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 P 55,000 A $12.1895(1) 1,405,000 I See Footnotes(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Panacea Innovation Ltd
(Last) (First) (Middle)
C/O MAPLES CORPORATE SERVICES LIMITED,
UGLAND HOUSE
(Street)
GRAND CAYMAN E9 KY1-1104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Huang James
(Last) (First) (Middle)
C/O MAPLES CORPORATE SERVICES LIMITED,
UGLAND HOUSE
(Street)
GRAND CAYMAN E9 KY1-1104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.83 to $12.44, inclusive. The Reporting Person undertake to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
2. Represents securities held by Panacea Venture Healthcare Fund II, L.P.
3. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd. ("Fund II GP") and Panacea Opportunity Fund I GP Company, Ltd. ("Opportunity Fund GP"), which are the general partners of Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. As a result, each of the Reporting Persons may be deemed to share beneficial ownership of the securities held of record by Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., but each disclaims such beneficial ownership.
Panacea Innovation Limited By: /s/ James Huang, Founding Managing Partner 08/19/2025
/s/ James Huang 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What shares were purchased in the ATRA Form 4 filed by Panacea Innovation Ltd?

The filing reports the acquisition of 55,000 shares of Atara common stock on 08/15/2025.

At what price were the ATRA shares purchased by the reporting persons?

The weighted-average price reported is $12.1895 per share, with purchases in the range $11.83 to $12.44.

What is the reported beneficial ownership after the transaction?

The filing reports 1,405,000 shares beneficially owned following the reported transaction, held indirectly.

Who are the reporting persons in the Form 4 for ATRA?

The reporting persons are Panacea Innovation Limited and James Huang, each indicated as a director and 10% owner.

Does the filing explain the ownership structure behind the holdings?

Yes. Footnotes state that Panacea entities hold securities through Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P. and that James Huang is the sole owner of Panacea Innovation Limited.
Stock ATRA logo
Atara Biotherape

NASDAQ:ATRA

ATRA Rankings

#4840 Ranked by Market Cap
N/A Ranked by Dividends

ATRA Latest News

Sep 3, 2025
Atara Biotherapeutics Announces Changes to Its Board of Directors
Aug 11, 2025
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
Jul 24, 2025
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Jul 24, 2025
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel庐) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Jul 15, 2025
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

ATRA Latest SEC Filings

Aug 20, 2025
[Form 4] Atara Biotherapeutics, Inc Insider Trading Activity
Aug 20, 2025
[Form 4] Atara Biotherapeutics, Inc Insider Trading Activity
Aug 19, 2025
[SCHEDULE 13D/A] Atara Biotherapeutics, Inc SEC Filing
Aug 18, 2025
[144] Atara Biotherapeutics, Inc SEC Filing
Aug 18, 2025
[144] Atara Biotherapeutics, Inc SEC Filing

ATRA Stock Data

89.89M
5.53M
21.29%
45.69%
3.53%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
THOUSAND OAKS